Chun Bao Yang
Directeur/Membre du Conseil chez SHANGHAI QINGPU FIRE-FIGHTING EQUIPMENT CO., LTD.
Profil
Chun Bao Yang currently works at Shanghai Qingpu Fire Fighting Equipment Co., Ltd., as Independent Non-Executive Director from 2000 and Shanghai Huashen Certified Public Accountants Ltd., as Accountant from 2011.
Mr. Yang also formerly worked at Mingyuan Medicare Development Co. Ltd., as Independent Non-Executive Director from 2014 to 2016.
Mr. Yang received his graduate degree in 1999 from Madonna University.
Postes actifs de Chun Bao Yang
| Sociétés | Poste | Début |
|---|---|---|
| SHANGHAI QINGPU FIRE-FIGHTING EQUIPMENT CO., LTD. | Directeur/Membre du Conseil | 01/10/2000 |
| Shanghai Huashen Certified Public Accountants Ltd. | Corporate Officer/Principal | 01/11/1973 |
Anciens postes connus de Chun Bao Yang
| Sociétés | Poste | Fin |
|---|---|---|
| MINGYUAN MEDICARE DEVELOPMENT CO., LTD. | Directeur/Membre du Conseil | 20/05/2016 |
Formation de Chun Bao Yang
| Madonna University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SHANGHAI QINGPU FIRE-FIGHTING EQUIPMENT CO., LTD. | Electronic Technology |
| Entreprise privées | 2 |
|---|---|
| Shanghai Huashen Certified Public Accountants Ltd. | |
Mingyuan Medicare Development Co. Ltd.
 Mingyuan Medicare Development Co. Ltd. BiotechnologyHealth Technology Mingyuan Medicare Development Co. Ltd. engages in provision of medicare solutions for the early detection and prevention of diseases particularly in China. It operates through the following segments: Protein Chips, Healthcare, Medical Centers Management, Individualized Target Therapy, and Bio-Drugs. The Protein Chips segment manufactures and distributes C-12 products to hospitals, medical centers, and life insurance companies in China. The Healthcare segment engages in the provision of sales and marketing campaign for HPV DNA testing kits and making important progress to register products for distribution to female patients at hospitals nationwide. The Medical Centers Management segment engages in the provision of healthcare services for residents living in cities. The Individualized Target Therapy segment specializes in molecular diagnostic kits for leukemia, lymphoma and individualised target cancer therapy. The Bio-Drugs segment engages in the development, production and commercialization of a new generation of non-specific nanotechnology immunomodulatory drugs known as non-cell Corynebacterium pavum products. The company was founded on May 8, 1989 and is headquartered in Hong Kong. | Health Technology |
